S&P 500 falls on pressure from retail stocks, weak jobless claims
Jonathan Biller, Executive Vice President and Chief Legal Officer at Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), recently executed a significant stock sale. According to a recent SEC filing, Biller sold 3,433 shares of the company’s common stock on February 11, 2025, at a weighted average price of $459.87 per share, totaling approximately $1.58 million. The transaction comes as Vertex, a prominent player in the biotechnology industry with a market capitalization of $116 billion, trades near InvestingPro’s Fair Value estimate. This transaction was conducted under a pre-established trading plan. Following this sale, Biller retains ownership of 16,330 shares. The company maintains strong financial health with a current ratio of 2.69 and operates with moderate debt levels. InvestingPro analysis reveals 8 additional key insights about Vertex’s financial position and growth prospects, available in the comprehensive Pro Research Report.
In other recent news, Vertex Pharmaceuticals has been the subject of several analyst reports. TD Cowen has reaffirmed its Buy rating and $525 price target for Vertex, highlighting its fourth-quarter performance where cystic fibrosis revenues reached $2.9 billion. The firm also noted that Vertex’s revenue is expected to grow 8% year-over-year by 2025, with significant contributions from the upcoming product, Journavx.
Truist Securities has raised its price target for Vertex to $520, maintaining a Buy rating. The firm expressed optimism about the market reception for Journavx, and also noted the potential of Alyftrek in treating cystic fibrosis. Meanwhile, BMO Capital Markets maintained its Outperform rating and $545 price target on Vertex, emphasizing the company’s growth potential and portfolio diversification through 2025.
On the other hand, Morgan Stanley (NYSE:MS) raised its price target for Vertex to $459, maintaining an Equalweight rating. The firm adjusted its outlook following Vertex’s recent financial performance and guidance update. Lastly, Scotiabank (TSX:BNS) analyst Greg Harrison updated the price target for Vertex to $450, maintaining a Sector Perform rating, following the company’s strong fourth-quarter performance in 2024. These are recent developments, and investors should take note of these assessments.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.